R. Sutherland

Basic science: (January 2009)

1. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang BL, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441–451. 2. Berg AO, Grp EW, Armstrong K, Botkin J, Calonge N, Haddow J, Hayes M, Kaye C, Phillips KA, Piper M, Richards CS, Scott JA, Strickland OL, Teutsch S. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009; 11: 66–73. 3. Bourguignon LYW, Xia WL, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NF kappa B-specific transcription activity leading to MDR1 and Bcl-x(L) gene expression and chemoresistance in breast tumor cells. J Biol Chem 2009; 284: 2657–2671. 4. Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009; 28: 306–312. 5. de Muga SV, Timpson P, Cubells L, Evans R, Hayes TE, Rentero C, Hegemann A, Reverter M, Leschner J, Pol A, Tebar F, Daly RJ, Enrich C, Grewal T. Annexin A6 inhibits Ras signalling in breast cancer cells. Oncogene 2009; 28: 363–377. 6. Ding SL, Yu JC, Chen ST, Hsu GC, Kuo SJ, Lin YH, Wu PE, Shen CY. Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis 2009; 30: 43–49. 7. Feres KJ, Ischenko I, Hayman MJ. The RON receptor tyrosine kinase promotes MSPindependent cell spreading and survival in breast epithelial cells. Oncogene 2009; 28: 279–288. 8. Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 2009; 42: 87–103. 9. Hu ZB, Liang J, Wang ZW, Tian T, Zhou XY, Chen JP, Miao RF, Wang Y, Wang XR, Shen HB. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 2009; 30: 79–84. 10. Kok M, Linn SC, Van Laar RK, Jansen M, van den Berg TM, Delahaye L, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JGM, Wessels LFA, Van’t Veer LJ, Berns E. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009; 113: 275–283. 11. Lower EE, Glass E, Blau R, Harman S. HER-2/ neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301–306. 12. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SGA, Eley JW. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113: 357–370. 13. Luo M, Fan HP, Nagy T, Wei HJ, Wang CR, Liu SL, Wicha MS, Guan JL. Mammary epithelialspecific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009; 69: 466–474. 14. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de The H, StoppaLyonnet D, Stern MH. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663–671. 15. Meijer D, Jansen M, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, First published online 14/07/09 BCO/850/2009/JW

Basic science: (May 2009)

1. Adamovic T, Roshani L, Chen L, Schaffer BS, Helou K, Levan G, Olsson B, Shull JD. Nonrandom pattern of chromosome aberrations in 17 b-estradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. Genes Chromosomes Cancer 2007; 46: 459–469. 2. Adams BD, Furneaux H, White BA. The microribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-a (ERa) and represses ERa messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21: 1132–1147. 3. Aupperlee MD, Haslam SZ. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 2007; 148: 2290–2300. 4. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007; 120: 2202–2207. 5. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, AlKuraya K, Janicke F, Sauter G, Simon R. Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007; 39: 655–660. 6. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870–874. 7. Kim H, Chen JJ, Yu XH. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007; 316: 1202–1205. 8. Li W, Xiao C, Vonderhaar BK, Deng CX. A role of estrogen/ERa signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 2007 May 14; [Epub ahead of print], doi:10.1038/sj.onc.1210527. 9. Liu BL, Ordonez-Ercan D, Fan ZY, Edgerton SM, Yang XH, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007; 120: 1874–1882. 10. Maiello MR, D’Alessio A, De Luca A, Carotenuto A, Rachiglio AM, Napolitano M, Cito L, Guzzo A, Normanno N. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat 2007; 102: 275–282. 11. McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERa-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene 2007 May 7; [Epub ahead of print], doi:10.1038/sj.onc.1210468. 12. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007; 120: 1883–1890. 13. Paterson AL, Pole JCM, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE, Wang YZ, Chin SF, Ylstra B, Caldas C, Edwards PAW. Coamplification of 8p 12 and 11q 13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 2007; 46: 427–439. 14. Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer – A mini review. Int J Cancer 2007; 120: 2061–2067. BCO/660/2007/JW

Basic science: (February 2008)

1. Arnes JB, Collett K, Akslen LA. Lesson of the month – independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008; 52: 370–380. 2. Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008; 27: 1106–1113. 3. Bergarnaschi A, Tagliabue E, Sorlie T, Naurne B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Menard S, Borresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357–367. 4. Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci USA 2008; 105: 3527–3532. 5. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G, Sabbah M. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 2008; 28: 1114–1123. 6. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 379–386. 7. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt ANJ, Crook T, Lord CJ, Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008; 13: 91–104. 8. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141–152. 9. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2008; 27: 1472–1477. 10. Levy N, Tatomer D, Herber CB, Zhao XY, Tang H, Sargeant T, Ball LJ, Summers J, Speed TP, Leitman DC. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008; 22: 287–303. 11. Liu HL, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Therap 2008; 7: 263–270. 12. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105: 1680–1685. 13. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S. ATF-2 controls transcription of Maspin and GADD45 a genes independently from p53 to suppress mammary tumors. Oncogene 2008; 27: 1045–1054. 14. Meijer D, Jansen M, Look M, Ruigrok-Ritstier K, Staveren I, Sieuwerts A, Agthoven T, Foekens J, Dorssers L, Berns E. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res Treat 2008; 10.1007/s10549-008-9934-3. 15. Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, Slavin JL, Moller A, Steel R, Pouliot N, Eckhardt BL, Henderson MA, Anderson RL. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 2008; 214: 337–346. BCO/830/2008/JW